EUVIMEDEUVIMED entdecken
Crossref

Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study)

Mehak Trikha, Laboni Sarkar iD, Aditya Dhanawat iD, Noorzia Syed, Himanshu Gujarathi, Manan Vora iD, A Sree Sivakumar Raja iD, Prabhat Bhargava iD, Anant Ramaswamy iD, Sarika Mandavkar, Avanish Saklani, Rajiv Kumar Kaushal iD und 4 weitere

JCO Global Oncology · 2024

DOI: 10.1200/go.24.00141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Mehak Trikha und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Parel, Mumbai, India. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Microsatellite Instability, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Standard-dose immune checkpoint inhibitors (SD-ICIs) are the standard of care as initial therapy in microsatellite instable-high (MSI-H) advanced/metastatic colorectal adenocarcinomas (mCRC), but there are preclinical data to suggest that low-dose ICIs (LD-ICI) might also have similar efficacy. MATERIALS AND METHODS A retrospective study of patients with MSI-H mCRC receiving ICIs between June 2017 and January 2023 was conducted. The primary end point of the study was 12-month progression-free survival (PFS), which was computed using the Kaplan-Meier method. RESULTS A total of 65 patients were available for analysis during the study period. Sixty patients (92%) received nivolumab, whereas the remaining received pembrolizumab. First-line ICIs were received by 18 patients (28%), whereas 47 patients (72%) received ICIs during later lines. Thirty patients (47%) received LD-ICIs (all received nivolumab), with the remaining receiving SD-ICIs (53%). At a median follow-up of 16.5 (95% CI, 11.8 to 21.2) months, median PFS was not reached in the entire cohort. The 12-month PFS rate in the LD-ICI cohort was 90%, whereas it was 75.8% in the SD-ICI cohort. There were no statistical differences in patients receiving ICIs as first-line therapy (12 months PFS—94.4%) or during later lines of therapy (12-month PFS—77.9%; P = .56). CONCLUSION ICIs in the current study show survivals which are similar to those seen in seminal trials in patients with MSI-H mCRC. Low-dose ICIs appear to work in MSI-H mCRC and should be explored prospectively in clinical trials. Patients with MSI-H status should be exposed to ICIs, whether initially or later during treatment, whenever feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsMicrosatellite InstabilityImmune Checkpoint InhibitorsImmunotherapyHumansMaleFemaleMiddle AgedRetrospective StudiesAgedNivolumabAdultAged, 80 and overAntibodies, Monoclonal, HumanizedNeoplasm MetastasisProgression-Free Survival

Substanzen

Immune Checkpoint InhibitorsNivolumabpembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Parel, Mumbai, India.
  • Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute HBNI, Mumbai, India.
  • Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute HBNI, Mumbai, India.
  • Department of Molecular Pathology, Tata Memorial Centre, Homi Bhabha National Institute HBNI, Mumbai, India.

ORCID-Profile: Laboni Sarkar, Aditya Dhanawat, Manan Vora, A Sree Sivakumar Raja, Prabhat Bhargava, Anant Ramaswamy, Rajiv Kumar Kaushal, Omshree Shetty, Subhash Yadav, Vikas Ostwal

Zitieren

APA

Trikha, M., Sarkar, L., Dhanawat, A., Syed, N., Gujarathi, H., Vora, M., Sivakumar Raja, A. S., Bhargava, P., Ramaswamy, A., Mandavkar, S., Saklani, A., Kaushal, R. K., Bal, M., Shetty, O., Yadav, S., & Ostwal, V. (2024). Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study). JCO Global Oncology. https://doi.org/10.1200/go.24.00141

Vancouver

Trikha M, Sarkar L, Dhanawat A, Syed N, Gujarathi H, Vora M, et al. Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study). JCO Global Oncology. 2024. doi:10.1200/go.24.00141

BibTeX
@article{Trikha2024,
  author = {Trikha, Mehak and Sarkar, Laboni and Dhanawat, Aditya and Syed, Noorzia and Gujarathi, Himanshu and Vora, Manan and Sivakumar Raja, A Sree and Bhargava, Prabhat and Ramaswamy, Anant and Mandavkar, Sarika and Saklani, Avanish and Kaushal, Rajiv Kumar and Bal, Munita and Shetty, Omshree and Yadav, Subhash and Ostwal, Vikas},
  title = {Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study)},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.24.00141}
}
Kostenlos starten →